Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCI-COG Pediatric MATCH - Phase 2 Subprotocol of Tazemetostat
NCT03213665Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2017
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of tazemetostat in solid tumor (advanced stage), non-Hodgkin lymphoma (NHL), histiocytic disorder, central nervous system tumor, sponsored by National Cancer Institute. Started Nov 2017; status: completed.
02
Drugs
tazemetostat
03
Conditions
solid tumor (advanced stage)non-Hodgkin lymphoma (NHL)histiocytic disordercentral nervous system tumor
Beyond the preview
Go deeper on NCT03213665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03213665.